Abstract
Endostar (a recombinant human endostatin), as a anti-angiogenesis agent, combined with chemotherapy is well-tolerated in patients with metastatic colorectal cancer, gastric cancer and advanced non-small cell lung cancer, but fewer reports are on cervical cancer. Safety and efficacy of endostar combined with platinum-based regimens in the first-line treatment of recurrence and metastatic cervical cancer remains unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
